definiens: shall mean glial progenitor ce ll and glial cell therapy products in the Field tha t are derived from the Cell Line using [COMPANY] ’s propr ietary differentiation technology, including such cell therapy products as modified or improved by Sa na . ” 4 . For clarity, no rights are granted under the See d Bank Agreement to use the Cell Line or Cell Line Derivatives ( as such terms are defined in the Seed Bank Agreement ) with any differentiation technology ( including any technology owned by Sana ), other than the [COMPANY] Technology . Sana, [COMPANY] and Hadasit agree that, subject to Sana ’s co mpliance with Section 4 of Amendment No . 1 to the Seed Bank Agreement, the assignment set forth i n this paragraph complies with Sections 3.5(c ), 3.6 and 13 of the Seed Bank Supply Agreement